{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:10:08Z","timestamp":1756807808552,"version":"3.44.0"},"reference-count":112,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Nephrolithiasis (KS) and metabolic bone diseases (MBDs) not linked to parathormone (osteoporosis, Paget\u2019s disease of bone and renal phosphate leak) are related as demonstrated by epidemiological and experimental data. Moreover, patients affected by monogenic kidney stone disorders (idiopathic hypercalciuria, primary hyperoxaluria, hypocitraturia, cystinuria and defects in purine metabolism) showed a bone phenotype. A significant economic and social burden is associated with KS and MBDs, due to high mortality and morbidity rate. Concerning this point of view, an integrated screening could be a cost-saving strategy. We suggest a new clinical management for patients affected by KS and MBDs. The assessment of bone mineral density by Dual X-ray absorptiometry and bone turnover markers should be proposed in KS patients. On the contrary, the evaluation of KS-related metabolic risk factor and an abdomen ultrasound exam should be offered to MBD patients. Moreover, in patients with early and\/or recurrent KS, an extended gene-panel should be suggested.<\/jats:p>","DOI":"10.4081\/aiua.2025.13870","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:08:48Z","timestamp":1750064928000},"source":"Crossref","is-referenced-by-count":0,"title":["Kidney stones and metabolic bone diseases not linked to parathyroid disfunction: a proposal for an integrated management"],"prefix":"10.4081","volume":"97","author":[{"given":"Anita","family":"Vergatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-0067","authenticated-orcid":false,"given":"Veronica","family":"Abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Della Monica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5256-6459","authenticated-orcid":false,"given":"Alfonso","family":"Varriale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1526-9346","authenticated-orcid":false,"given":"Simone","family":"Magelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4971-2111","authenticated-orcid":false,"given":"Francesca","family":"Garofano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanfranco","family":"D'Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"De Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Rendina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Karsenty G. The complexities of skeletal biology. Nature 2003; 423:316-318.","key":"181789","DOI":"10.1038\/nature01654"},{"doi-asserted-by":"crossref","unstructured":"Feng X. Chemical and biochemical basis of cell-bone matrix interaction in health and disease. Curr Chem Biol 2009; 3:189-196.","key":"181790","DOI":"10.2174\/2212796810903020189"},{"doi-asserted-by":"crossref","unstructured":"Arias CF, Herrero MA, Echeverri LF, et al. Bone remodeling: a tissue-level process emerging from cell-level molecular algorithms. PLoS One 2018; 13:e0204171.","key":"181791","DOI":"10.1371\/journal.pone.0204171"},{"doi-asserted-by":"crossref","unstructured":"\u0160romov\u00e1 V, Sobola D, Kaspar P. A brief review of bone cell function and importance. Cells 2023;12:2576.","key":"181792","DOI":"10.3390\/cells12212576"},{"doi-asserted-by":"crossref","unstructured":"Florencio-Silva R, Sasso GR, Sasso-Cerri E, et al. biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int 2015; 2015:421746.","key":"181793","DOI":"10.1155\/2015\/421746"},{"doi-asserted-by":"crossref","unstructured":"Guntur AR, Rosen CJ. Bone as an endocrine organ. Endocr Pract 2012;18:758-62.","key":"181794","DOI":"10.4158\/EP12141.RA"},{"doi-asserted-by":"crossref","unstructured":"Du Y, Zhang L, Wang Z, et al. Endocrine regulation of extra-skeletal organs by bone-derived secreted protein and the effect of mechanical stimulation. Front Cell Dev Biol 2021; 9:778015.","key":"181795","DOI":"10.3389\/fcell.2021.778015"},{"doi-asserted-by":"crossref","unstructured":"Karsenty G. Osteocalcin: A multifaceted bone-derived hormone. Annu Rev Nutr. 2023;43:55-71.","key":"181796","DOI":"10.1146\/annurev-nutr-061121-091348"},{"doi-asserted-by":"crossref","unstructured":"Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol 2007;143:31-48.","key":"181797","DOI":"10.1159\/000098223"},{"doi-asserted-by":"crossref","unstructured":"Cornish J, Gillespie MT, Callon KE, et al. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology 2003;144:1194-201.","key":"181798","DOI":"10.1210\/en.2002-220936"},{"doi-asserted-by":"crossref","unstructured":"Mirosavljevic D, Quinn JM, Elliott J, et al. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 2003;18:984-93.","key":"181799","DOI":"10.1359\/jbmr.2003.18.6.984"},{"doi-asserted-by":"crossref","unstructured":"Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408:600-5.","key":"181800","DOI":"10.1038\/35046102"},{"doi-asserted-by":"crossref","unstructured":"Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-9.","key":"181801","DOI":"10.1038\/46303"},{"doi-asserted-by":"crossref","unstructured":"Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2010 1; 6:4.","key":"181802","DOI":"10.1038\/nrrheum.2009.280"},{"doi-asserted-by":"crossref","unstructured":"Su N, Yang J, Xie Y, et al. Bone function, dysfunction and its role in diseases including critical illness. Int J Biol Sci 2019; 15:776-87.","key":"181803","DOI":"10.7150\/ijbs.27063"},{"doi-asserted-by":"crossref","unstructured":"Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J 2007; 83:509-17.","key":"181804","DOI":"10.1136\/pgmj.2007.057505"},{"doi-asserted-by":"crossref","unstructured":"Rossini M, Adami S, Bertoldo F, et al. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 2016; 68:1-39.","key":"181805","DOI":"10.4081\/reumatismo.2016.870"},{"doi-asserted-by":"crossref","unstructured":"Rajan R, Cherian KE, Kapoor N, Paul TV. Trabecular bone score-an emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2020; 24:237-43.","key":"181806","DOI":"10.4103\/ijem.IJEM_147_20"},{"doi-asserted-by":"crossref","unstructured":"Hans D, M\u00e9trailler A, Gonzalez Rodriguez E, et al. Quantitative ultrasound (QUS) in the management of osteoporosis and assessment of fracture risk: an update. Adv Exp Med Biol 2022;1364:7-34.","key":"181807","DOI":"10.1007\/978-3-030-91979-5_2"},{"doi-asserted-by":"crossref","unstructured":"Brett AD, Brown JK. Quantitative computed tomography and opportunistic bone density screening by dual use of computed tomography scans. J Orthop Translat 2015;3:178-84.","key":"181808","DOI":"10.1016\/j.jot.2015.08.006"},{"doi-asserted-by":"crossref","unstructured":"Diez-Perez A, Brandi ML, Al-Daghri N, et al. Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 2019;31:1375-89.","key":"181809","DOI":"10.1007\/s40520-019-01294-4"},{"doi-asserted-by":"crossref","unstructured":"Di Paola M, Gatti D, Viapiana O, et al. Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int 2019; 30:391-402.","key":"181810","DOI":"10.1007\/s00198-018-4686-3"},{"doi-asserted-by":"crossref","unstructured":"Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem 2012;45:920-927.","key":"181811","DOI":"10.1016\/j.clinbiochem.2012.03.023"},{"doi-asserted-by":"crossref","unstructured":"Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-36.","key":"181812","DOI":"10.1002\/jbmr.5650020510"},{"doi-asserted-by":"crossref","unstructured":"Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991;28:287-335.","key":"181813","DOI":"10.3109\/10408369109106867"},{"doi-asserted-by":"crossref","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 2016; 67:559-66.","key":"181814","DOI":"10.1053\/j.ajkd.2015.06.023"},{"doi-asserted-by":"crossref","unstructured":"Brown JP, Don-Wauchope A, Douville P, et al. Current use of bone turnover markers in the management of osteoporosis. Clin Biochem 2022;109-110:1-10.","key":"181815","DOI":"10.1016\/j.clinbiochem.2022.09.002"},{"doi-asserted-by":"crossref","unstructured":"Shetty S, Kapoor N, Bondu JD, et al. Bone turnover markers: emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2016; 20:846-52.","key":"181816","DOI":"10.4103\/2230-8210.192914"},{"doi-asserted-by":"crossref","unstructured":"Gambaro G, Croppi E, Coe F, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 2016; 29:715-34.","key":"181817","DOI":"10.1007\/s40620-016-0329-y"},{"doi-asserted-by":"crossref","unstructured":"Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investig Clin Urol 2017;58:299-306.","key":"181818","DOI":"10.4111\/icu.2017.58.5.299"},{"doi-asserted-by":"crossref","unstructured":"Tu\u0308rk C, Petr\u00edk A, Sarica K, et al. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 2016; 69:468-74.","key":"181819","DOI":"10.1016\/j.eururo.2015.07.040"},{"doi-asserted-by":"crossref","unstructured":"Ghani KR, Rojanasarot S, Cutone B, et al. Economic burden of complicated ureteral stent removal in patients with kidney stone disease in the USA. J Comp Eff Res 2022; 11:1253-61.","key":"181820","DOI":"10.2217\/cer-2022-0153"},{"unstructured":"Hyams ES, Matlaga BR. Economic impact of urinary stones. Transl Androl Urol. 2014;3:4200.","key":"181821"},{"doi-asserted-by":"crossref","unstructured":"Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115:2598-608.","key":"181822","DOI":"10.1172\/JCI26662"},{"doi-asserted-by":"crossref","unstructured":"Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol 2011; 6:121-45.","key":"181823","DOI":"10.1146\/annurev-pathol-011110-130203"},{"unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020 14; 396:1562.","key":"181824"},{"doi-asserted-by":"crossref","unstructured":"Marcellusi A, Rotundo MA, Nardone C, et al. Osteoporosis: economic burden of disease in Italy. Clin Drug Investig 2020; 40:449-58.","key":"181825","DOI":"10.1007\/s40261-020-00904-8"},{"doi-asserted-by":"crossref","unstructured":"Cundy T, et al. Metabolic bone disease in clinical biochemistry: metabolic and clinical aspects, 3rd Ed, 2014. p 604.","key":"181826","DOI":"10.1016\/B978-0-7020-5140-1.00031-6"},{"doi-asserted-by":"crossref","unstructured":"Golden SH, Robinson KA, Saldanha I, et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94:1853-78.","key":"181827","DOI":"10.1210\/jc.2008-2291"},{"doi-asserted-by":"crossref","unstructured":"Appelman-Dijkstra NM, Oei HLDW, Vlug AG, Winter EM. The effect of osteoporosis treatment on bone mass. Best Pract Res Clin Endocrinol Metab 2022; 36:101623.","key":"181828","DOI":"10.1016\/j.beem.2022.101623"},{"doi-asserted-by":"crossref","unstructured":"Denburg MR, Leonard MB, Haynes K, et al. Risk of fracture in urolithiasis: a population-based cohort study using the health improvement network. Clin J Am Soc Nephrol 2014; 9:2133-40.","key":"181829","DOI":"10.2215\/CJN.04340514"},{"doi-asserted-by":"crossref","unstructured":"Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25:2359-81.","key":"181830","DOI":"10.1007\/s00198-014-2794-2"},{"doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Garach A, Garc\u00eda-Fontana B, Mu\u00f1oz-Torres M. Nutrients and dietary patterns related to osteoporosis. Nutrients 2020; 12:1986.","key":"181831","DOI":"10.3390\/nu12071986"},{"doi-asserted-by":"crossref","unstructured":"Sorensen MD, Chi T, Shara NM, et al. Activity, energy intake, obesity, and the risk of incident kidney stones in postmenopausal women: a report from the Women's Health Initiative. J Am Soc Nephrol 2014; 25:362-9.","key":"181832","DOI":"10.1681\/ASN.2013050548"},{"doi-asserted-by":"crossref","unstructured":"Booth FW, Roberts CK, Thyfault JP, et al. Role of inactivity in chronic diseases: evolutionary insight and pathophysiological mechanisms. Physiol Rev 2017; 97:1351-402.","key":"181833","DOI":"10.1152\/physrev.00019.2016"},{"doi-asserted-by":"crossref","unstructured":"Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020;74:1498-513.","key":"181834","DOI":"10.1038\/s41430-020-0558-y"},{"doi-asserted-by":"crossref","unstructured":"Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol 2020; 17:407-421.","key":"181835","DOI":"10.1038\/s41585-020-0332-x"},{"doi-asserted-by":"crossref","unstructured":"Pak CY, Sakhaee K, Moe OW, et al. Defining hypercalciuria in nephrolithiasis. Kidney Int 2011; 80:777-82.","key":"181836","DOI":"10.1038\/ki.2011.227"},{"doi-asserted-by":"crossref","unstructured":"Giannini S, Nobile M, Dalle Carbonare L, et al. Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol 2003;149:209-13.","key":"181837","DOI":"10.1530\/eje.0.1490209"},{"doi-asserted-by":"crossref","unstructured":"Eller-Vainicher C, Cairoli E, Zhukouskaya VV, et al. Prevalence of subclinical contributors to low bone mineral density and\/or fragility fracture. Eur J Endocrinol 2013;169:225-37.","key":"181838","DOI":"10.1530\/EJE-13-0102"},{"doi-asserted-by":"crossref","unstructured":"Rebsamen MC, Sun J, Norman AW, Liao JK. 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91:17-24.","key":"181839","DOI":"10.1161\/01.RES.0000025269.60668.0F"},{"doi-asserted-by":"crossref","unstructured":"Trinchieri A. Bone mineral content in calcium renal stone formers. Urol Res 2005; 33:247-53.","key":"181840","DOI":"10.1007\/s00240-005-0498-y"},{"doi-asserted-by":"crossref","unstructured":"Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009; 41:926-30.","key":"181841","DOI":"10.1038\/ng.404"},{"doi-asserted-by":"crossref","unstructured":"Kleeman CR, Bohannan J, Bernstein D, et al. Effect of variations in sodium intake on calcium excretion in normal humans. Pro Soc Exp Biol Med 1964; 115:29-32.","key":"181842","DOI":"10.3181\/00379727-115-28821"},{"doi-asserted-by":"crossref","unstructured":"Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354:669-83.","key":"181843","DOI":"10.1056\/NEJMx060015"},{"doi-asserted-by":"crossref","unstructured":"Heaney RP. Calcium supplementation and incident kidney stone risk: a systematic review. J Am Coll Nutr 2008; 27:519-27.","key":"181844","DOI":"10.1080\/07315724.2008.10719734"},{"doi-asserted-by":"crossref","unstructured":"Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77-84.","key":"181845","DOI":"10.1056\/NEJMoa010369"},{"doi-asserted-by":"crossref","unstructured":"Nordin BE, Need AG, Steurer T, et al. Nutrition, osteoporosis, and aging. Ann NY Acad Sci. 1998; 854:336-51.","key":"181846","DOI":"10.1111\/j.1749-6632.1998.tb09914.x"},{"unstructured":"Nouvenne A, Meschi T, Guerra A, et al. Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab 2008; 5:135-41.","key":"181847"},{"doi-asserted-by":"crossref","unstructured":"Thom JA, Morris JE, Bishop A, Blacklock NJ. The influence of refined carbohydrate on urinary calcium excretion. Br J Urol 1978; 50:459-464.","key":"181848","DOI":"10.1111\/j.1464-410X.1978.tb06191.x"},{"unstructured":"DiNicolantonio JJ, Mehta V, Zaman SB, O'Keefe JH. Not salt but sugar as aetiological in osteoporosis: a review. Mo Med 2018;115:247-52.","key":"181849"},{"doi-asserted-by":"crossref","unstructured":"Rendina D, De Filippo G, Zampa G, et al. Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome. Nephrol Dial Transplant 2011; 26:2256-63.","key":"181850","DOI":"10.1093\/ndt\/gfq664"},{"doi-asserted-by":"crossref","unstructured":"Abate V, Vergatti A, Fiore A, et al. Low potassium intake: a common risk factor for nephrolithiasis in patients with high blood pressure. High Blood Press Cardiovasc Prev 2023;30:343-50.","key":"181851","DOI":"10.1007\/s40292-023-00587-0"},{"doi-asserted-by":"crossref","unstructured":"Tebben PJ, Milliner DS, Horst RL, et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 2012;97:E423-7.","key":"181852","DOI":"10.1210\/jc.2011-1935"},{"doi-asserted-by":"crossref","unstructured":"Lacey DL, Grosso LE, Moser SA, et al. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest 1993; 91:1731-42.","key":"181853","DOI":"10.1172\/JCI116383"},{"doi-asserted-by":"crossref","unstructured":"Lucato P, Trevisan C, Stubbs B, et al. Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis. Osteoporos Int 2016; 27:3155-64.","key":"181854","DOI":"10.1007\/s00198-016-3658-8"},{"doi-asserted-by":"crossref","unstructured":"Taylor EN, Feskanich D, Paik JM, Curhan GC. Nephrolithiasis and risk of incident bone fracture. J Urol 2016; 195:1482-6.","key":"181855","DOI":"10.1016\/j.juro.2015.12.069"},{"doi-asserted-by":"crossref","unstructured":"Ganesan C, Thomas IC, Romero R, et al. Osteoporosis, fractures, and bone mineral density screening in veterans with kidney stone disease. J Bone Miner Res 2021;36:872-8.","key":"181856","DOI":"10.1002\/jbmr.4260"},{"doi-asserted-by":"crossref","unstructured":"Dhayat NA, Schneider L, Popp AW, et al. Predictors of bone mineral density in kidney stone formers. Kidney Int Rep 2021; 7:558-67.","key":"181857","DOI":"10.1016\/j.ekir.2021.12.003"},{"doi-asserted-by":"crossref","unstructured":"Sakhaee K, Maalouf NM, Poindexter J, et al. Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. J Urol 2017; 197:1472-77.","key":"181858","DOI":"10.1016\/j.juro.2017.01.002"},{"doi-asserted-by":"crossref","unstructured":"Fink HA, Litwack-Harrison S, Taylor BC, et al. Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the Osteoporotic Fractures in Men (MrOS) Study. Osteoporos Int 2017; 28:419-20.","key":"181859","DOI":"10.1007\/s00198-016-3805-2"},{"doi-asserted-by":"crossref","unstructured":"Carbone LD, Hovey KM, Andrews CA, et al. urinary tract stones and osteoporosis: findings from the women's health initiative. J Bone Miner Res 2015; 30:2096-102.","key":"181860","DOI":"10.1002\/jbmr.2553"},{"doi-asserted-by":"crossref","unstructured":"Rendina D, D'Elia L, Evangelista M, et al. Osteoporosis is a predictive factor for nephrolithiasis in an adult free-living caucasian population from southern italy: a longitudinal retrospective study based on a general practice database. Calcif Tissue Int 2020; 107:446-52.","key":"181861","DOI":"10.1007\/s00223-020-00737-9"},{"doi-asserted-by":"crossref","unstructured":"Rendina D, De Filippo G, Iannuzzo G, et al. Idiopathic osteoporosis and nephrolithiasis: two sides of the same coin? Int J Mol Sci 2020;21:8183.","key":"181862","DOI":"10.3390\/ijms21218183"},{"doi-asserted-by":"crossref","unstructured":"Gennari L, Rendina D, Falchetti A, Merlotti D. Paget's disease of bone. Calcif Tissue Int 2019;104:483-500.","key":"181863","DOI":"10.1007\/s00223-019-00522-3"},{"doi-asserted-by":"crossref","unstructured":"Rendina D, De Filippo G, Merlotti D, et al. increased prevalence of nephrolithiasis and hyperoxaluria in paget disease of bone. J Clin Endocrinol Metab 2020;105:dgaa576.","key":"181864","DOI":"10.1210\/clinem\/dgaa576"},{"doi-asserted-by":"crossref","unstructured":"Pri\u00e9 D, Friedlander G. Genetic disorders of renal phosphate transport. N Engl J Med 2010;362:2399-409.","key":"181865","DOI":"10.1056\/NEJMra0904186"},{"doi-asserted-by":"crossref","unstructured":"Wagner CA, Egli-Spichtig D, Rubio-Aliaga I. Updates on renal phosphate transport. Curr Opin Nephrol Hypertens 2025;34:269-75.","key":"181866","DOI":"10.1097\/MNH.0000000000001090"},{"doi-asserted-by":"crossref","unstructured":"Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab. 2009; 27:392-401.","key":"181867","DOI":"10.1007\/s00774-009-0079-1"},{"doi-asserted-by":"crossref","unstructured":"Berndt TJ, Schiavi S, Kumar R. \"Phosphatonins\" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005; 289:F1170-82.","key":"181868","DOI":"10.1152\/ajprenal.00072.2005"},{"doi-asserted-by":"crossref","unstructured":"Alon US. Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr 2011;170:545-54.","key":"181869","DOI":"10.1007\/s00431-010-1382-5"},{"doi-asserted-by":"crossref","unstructured":"Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol 2010;25:603-8.","key":"181870","DOI":"10.1007\/s00467-009-1384-6"},{"doi-asserted-by":"crossref","unstructured":"Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005;289:F1088-95.","key":"181871","DOI":"10.1152\/ajprenal.00474.2004"},{"doi-asserted-by":"crossref","unstructured":"Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers 2017; 3:17044.","key":"181872","DOI":"10.1038\/nrdp.2017.44"},{"doi-asserted-by":"crossref","unstructured":"Pri\u00e9 D, Ravery V, Boccon-Gibod L, Friedlander G. Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 2001; 60:272-276.","key":"181873","DOI":"10.1046\/j.1523-1755.2001.00796.x"},{"doi-asserted-by":"crossref","unstructured":"Pri\u00e9 D, Beck L, Silve C, Friedlander G. Hypophosphatemia and calcium nephrolithiasis. Nephron Exp Nephrol 2004; 98:e50-4.","key":"181874","DOI":"10.1159\/000080256"},{"doi-asserted-by":"crossref","unstructured":"Pri\u00e9 D, Huart V, Bakouh N, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2\u00b0 sodium-phosphate cotransporter. N Engl J Med 2002; 347:983-91.","key":"181875","DOI":"10.1056\/NEJMoa020028"},{"doi-asserted-by":"crossref","unstructured":"Rendina D, Mossetti G, De Filippo G, et al. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab 2006;91:959-63.","key":"181876","DOI":"10.1210\/jc.2005-1606"},{"doi-asserted-by":"crossref","unstructured":"Rendina D, Esposito T, Mossetti G, et al. A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis. J Clin Endocrinol Metab 2012;97:E840-4.","key":"181877","DOI":"10.1210\/jc.2011-1528"},{"doi-asserted-by":"crossref","unstructured":"Enlund-Cerullo M, Holmlund-Suila E, Valkama S, et al. Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants. Front Genet 2023; 14:1192368.","key":"181878","DOI":"10.3389\/fgene.2023.1192368"},{"doi-asserted-by":"crossref","unstructured":"van't Hoff WG. Aetiological factors in paediatric urolithiasis. Nephron Clin Pract 2004;98:c45-c48.","key":"181879","DOI":"10.1159\/000080251"},{"doi-asserted-by":"crossref","unstructured":"Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008; 28:120-32.","key":"181880","DOI":"10.1016\/j.semnephrol.2008.01.005"},{"doi-asserted-by":"crossref","unstructured":"Sargent JD, Stukel TA, Kresel J, Klein RZ. Normal values for random urinary calcium to creatinine ratios in infancy. J Pediatr 1993; 123:393-7.","key":"181881","DOI":"10.1016\/S0022-3476(05)81738-X"},{"doi-asserted-by":"crossref","unstructured":"Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 1980;69:19-30.","key":"181882","DOI":"10.1016\/0002-9343(80)90521-5"},{"doi-asserted-by":"crossref","unstructured":"Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int 2007;71:808-15.","key":"181883","DOI":"10.1038\/sj.ki.5002181"},{"doi-asserted-by":"crossref","unstructured":"Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR. Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant 2002;17:1396-401.","key":"181884","DOI":"10.1093\/ndt\/17.8.1396"},{"doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Nieto V, Navarro JF, Monge M, Garc\u00eda-Rodr\u00edguez VE. Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephron Clin Pract 2003; 94:c89-93.","key":"181885","DOI":"10.1159\/000072491"},{"unstructured":"Caudarella R, Vescini F, Buffa A, et al. Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors. J Nephrol 2003;16:260-6.","key":"181886"},{"doi-asserted-by":"crossref","unstructured":"Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013 28;369:2168.","key":"181887","DOI":"10.1056\/NEJMx130050"},{"doi-asserted-by":"crossref","unstructured":"Bacchetta J, Boivin G, Cochat P. Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 2016;31:1-6.","key":"181888","DOI":"10.1007\/s00467-015-3048-z"},{"unstructured":"Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol 2009; 11:134-44.","key":"181889"},{"doi-asserted-by":"crossref","unstructured":"Frassetto L, Banerjee T, Powe N, Sebastian A. Acid balance, dietary acid load, and bone effects-a controversial subject. Nutrients 2018;10:517.","key":"181890","DOI":"10.3390\/nu10040517"},{"doi-asserted-by":"crossref","unstructured":"Pak CY, Peterson RD, Poindexter J. Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. J Urol 2002;168:31-4.","key":"181891","DOI":"10.1016\/S0022-5347(05)64825-2"},{"doi-asserted-by":"crossref","unstructured":"Prot-Bertoye C, Lebbah S, Daudon M, et al. CKD and its risk factors among patients with cystinuria. Clin J Am Soc Nephrol 2015; 10:842-51.","key":"181892","DOI":"10.2215\/CJN.06680714"},{"doi-asserted-by":"crossref","unstructured":"Peters T, Thaete C, Wolf S, et al. A mouse model for cystinuria type I. Hum Mol Genet 2003;12:2109-120.","key":"181893","DOI":"10.1093\/hmg\/ddg189"},{"doi-asserted-by":"crossref","unstructured":"Bijelic R, Milicevic S, Balaban J. Incidence of osteoporosis in patients with urolithiasis. Med Arch 2014; 68:335-8.","key":"181894","DOI":"10.5455\/medarh.2014.68.335-338"},{"doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio V, Capolongo G, Caletti C et al. Bone mineral density assessment in patients with cystinuria. J Nephrol 2025;38:163-9.","key":"181895","DOI":"10.1007\/s40620-024-02012-8"},{"doi-asserted-by":"crossref","unstructured":"Sampat R, Fu R, Larovere LE, et al. Mechanisms for phenotypic variation in Lesch-Nyhan disease and its variants. Hum Genet 2011;129:71-8.","key":"181896","DOI":"10.1007\/s00439-010-0901-9"},{"doi-asserted-by":"crossref","unstructured":"Chen F, Wang Y, Guo Y, et al. Specific higher levels of serum uric acid might have a protective effect on bone mineral density within a Chinesepopulation over 60 years old: a cross-sectional study from northeast China. Clin Interv Aging 2019; 14:1065-73.","key":"181897","DOI":"10.2147\/CIA.S186500"},{"doi-asserted-by":"crossref","unstructured":"Dalbeth N, Becce F, Botson JK, et al. Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy. Rheumatology (Oxford) 2022;61:4898-904.","key":"181898","DOI":"10.1093\/rheumatology\/keac173"},{"unstructured":"Hyams ES, Matlaga BR. Economic impact of urinary stones. Transl Androl Urol 2014;3:278-83.","key":"181899"},{"doi-asserted-by":"crossref","unstructured":"Marcellusi A, Rotundo MA, Nardone C, et al. Osteoporosis: economic burden of disease in Italy. Clin Drug Investig 2020; 40:449-58.","key":"181900","DOI":"10.1007\/s40261-020-00904-8"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/13870\/13142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/13870\/13142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:37:01Z","timestamp":1756805821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/view\/13870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":112,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2025.13870","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"type":"electronic","value":"2282-4197"},{"type":"print","value":"1124-3562"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}